Member Info for Diversified

I think it’s been said the well researched are now positioned with a comfortable level of exposure going into what promises to be a news rich period, end of quarter.

Clevergen

As a rule we tend to get an update on Clevergen every 3 months. This would imply that the next update is due at the beginning of September.

Partnering for Clevergen could take place at any point.

Hibiscus

Said to be initiated in Q3 following completion of third party funding and regulatory approval.

WHO

You would of thought that given the noise coming from some who are participating in or are in control of the solidarity trial that the results would come by the end of the quarter.

New treatment

We then have this third treatment that is waiting for patent approval.

Secret weapon

Some have referred to the secret weapon, I’m lost, what is this?

Conclusion (imo)

A bottleneck of news flow over the next 5 weeks will lead to a further material rerating of the share price in anticipation of the solidarity results. At which point it’s outcome will dictate the near term share price movement until other updates such as Remap cap, Clevergen, Hibiscus can either sustain or change sentiment.

I personally cannot see the share price languishing back to a comfortable 400p and this weeks higher high and encouraging data about interferon should create a new higher base.

Very exciting times. GL everyone.

https://trialbulletin.com/lib/entry/ct-04521400

High or low dose IFN B1a

‘In a current study, the efficacy of IFN-ß 1a in COVID-19 patients were evaluated, and they found than IFN-ß 1a reduced the disease symptoms.’

Will be interesting to see the results of this, and although the beta will be delivered via injection, this is further coverage for the treatment and the ever expanding positive sentiment towards it.

In the the middle of the street, my house :-)

‘Meta-analysis of 3 sets of studies with 990, 454, and 1480 patients receiving Type I interferon therapyrevealed that there were no significant associations between receiving Type I interferon therapy, comparedto standard of care, andICU admittance, requiring mechanical ventilation, or developing a severe or critical case of COVID-19, respectively (p>0.05; Figure 3B; Figure 3C; Figure 3D).[28-36]The analyses included 97, 167, and 537 control patients, respectively. The data exhibitedvery high heterogeneity in cases of ICU admittance and disease severity (both I2>90%), but relatively lowin the case of mechanical ventilation (I2=12%). In the analyses of the 803 and 1415 Type I interferon receiving patients, intervention therapy wasrespectively associated with higher odds of being discharged (OR, 1.89; 95% CI, 1.00 –3.59; p=0.05; N=895; Figure 3E), and significantly lower odds of mortality (OR, 0.19; 95% CI, 0.04–0.85); p=0.03, N=1906; Figure 3A), when compared to standard of care. The studies included in these analyses enlisted 92 and 491 control patients, respectively. Discharge data exhibited very low heterogeneity (I2=0%), while mortality data demonstrated very high heterogeneity (I2=90%).’

I think this as good as confirms that c ‘Administering an IV formulation to strengthen the body's own IFN beta production - its first line of defence against viral infection - provides optimal exposure to the lung vasculature, which is what we believe critically ill patients need.(ref: RNS 18.8.20)’ with the key word being critical. It confirms what Traumakine is all about, the probability that the treatment leads to a significant reduction in mortality from those suffering ADRS.

That’s good enough for me, it derisks the forthcoming results significantly and provides provides justification as to why IFN-B1a is being included in the major COVID trials worldwide.

The PDF makes very nice bedtime reading:

https://www.medrxiv.org/content/10.1101/2020.08.10.20172189v1.full.pdf+html

Thank you, i think we have some great informative posters on here including yourself. It would be great to see a positive outcome for everyone involved.

This guy has nearly 300k twitter followers and is the real deal.

‘ Type I interferon treatment is associated with positive clinical outcomes regarding mortality and discharge’

https://twitter.com/erictopol/status/1296140581458989056?s=21

https://www.nytimes.com/2020/08/04/health/coronavirus-immune-system.html

Watch people buy the sh*t out of interferon Covid stocks

Great find. Markku did say in a proactive interview that the Hibiscus study will also allow for administration of Traumakine earlier on in the cycle which would be justified by the article you have shared.

I really can’t see why 4.6m has been invested in further ramping up the master batches for future production unless they were confident that Traumakine would be a winner.

I really can’t help but think that everything is pointing towards a positive outcome.

?

Nice big delayed trades. It’s good to see.

£5 has provided some resistance again but this could be broken at any point. We have lots of newsflow still due and the higher the price is prior to trial results the faster the rerating will happen if positive.

A few new posters today which is nice to see, good or bad.

I don’t understand the haters who are over at SNG, surely this is about a successful treatment and not competition of which their is plenty of space for all.

Wasn’t a who press conference yesterday, could be an omen

I noticed that N, if the headline RNS included the words covid you know it would gain more traction like others have done. It’s good to be invested in a company rather than a pump though.

It’s both injection and intravenous. Our treatment is administered at critical stage, unlike the Hibiscus trial which aims to administer earlier in the cycle.

They make the master batches using their patented tech to provide to the manufacturer for commercial production, but nice try ;-)

This could see Helsinki knocking on the door of £5.50/£6.00 plus today as it is already at £4.90 as of yesterday.

We definitely have some catching up to do. Updates to come:

- Hibiscus by end of quarter
- Third treatment, new drug
- Trial results
- Clevergen update by end of quarter
- Interim results

Now we have £4.6m committed towards the development of T and a commercial production partner. This is a considerable financial commitment, and a commitment you wouldn’t make unless you had been flying around the world seeing T gain commercial traction to justify it.

Hands are tied when it comes to updating the market on the two ongoing trials as it will be investigators that will be updating the world and we will have to provide an intraday update to comment on those reports, but again, all looking very positive as a monotherapy.

Hibiscus looks like it requires FDA approval, but the treatment alongside standard of care and more importantly dexamethasone goes to show that it is playing alongside the big boys. A trial that wouldn’t be needed if the US was still working in conjunction with the WHO. But this will be further commercial/global attention of our drug at the cost of a third party.

All in all, an update can come at any time, and according to those WHO are facilitating the trial, an update will come in the near future.

Didn’t happen today. They have also been very quite. No smoke without fire.

Still very quite here considering, completely under the radar.

You have a limit on it big d?